Login to Your Account

GSK scandal aftermath leads to a rise of beefed up internal controls

By Shannon Ellis
Staff Writer

Wednesday, August 13, 2014
HONG KONG – It's been more than a year since Chinese authorities leveled allegations against Glaxosmithkline plc (GSK) for corrupt activities amounting to almost $500 million in bribes, setting off an industrywide crackdown that has garnered the attention of not only the Chinese, but also the U.S. and UK anti-corruption authorities.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription